FUNDAMENTALS · Fundamentals · JP Healthcare

Value HR (6078) Fundamentals 2026 — P/E 66.7x, Revenue Analysis | SniperIQ

Value HR (6078) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥40.0B, trading at ¥1496.00 on the JPX. This SniperIQ fundamentals page covers Value HR's valuation (P/E 66.7x, P/B 6.0x), profitability (net margin 5.8%), revenue (¥10.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥40.0B
P/E (TTM)66.7x
Net Margin5.8%
Revenue (FY25)¥10.1B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Value HR's market cap?

Value HR (6078) has a market capitalization of approximately ¥40.0B, trading at ¥1496.00 on the JPX. Market cap moves with the live share price.

What is Value HR's P/E ratio?

Value HR's trailing twelve-month P/E ratio is 66.7x, with a price-to-book (P/B) of 6.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Value HR?

Value HR runs a net profit margin of 5.8%, a gross margin of 27.9%, and an operating margin of 8.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Value HR generate?

Value HR reported revenue of ¥10.1B for fiscal year 2025, with net income of ¥629M and earnings per share (EPS) of 23.55. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Value HR pay a dividend?

Value HR offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Value HR financially healthy?

Value HR carries a debt-to-equity ratio of 0.86x and a current ratio of 0.97x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Value HR a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Value HR (6078) the key facts are: market cap ¥40.0B, P/E 66.7x, revenue ¥10.1B, 52-week range 1321-1899. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Value HR's full fundamentals live

Get Value HR's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: ResMed (RMD) fundamentals · Guangzhou Baiyunshan Pharmaceutical Holdings (0874) fundamentals · Seikagaku (4548) fundamentals · Revolution Medicines (RVMD) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons